Effective drug monitoring in Europe depends on strong cooperation with Member States. In a new publication out today, we outline the key features of the Reitox Alliance, a new partnership framework between the EUDA and the national focal points (NFPs) of the Reitox network. The publication (Reitox Alliance operating framework) sets out the scope of the Alliance, the partners involved, its core tasks and governance arrangements.
Adopted by our Management Board in December 2025, the Reitox Alliance replaces the previous Reitox operating framework (in place since 2003) and aligns the…
Read more
This month, Cyprus assumed the rotating Presidency of the Council of the European Union, under the overarching motto ‘An Autonomous Union. Open to the World’. The motto reflects a forward-looking approach that combines internal strength and independence with openness, cooperation and global engagement.
The Cyprus Presidency is guided by five broad priorities:
Autonomy through security, defence readiness and preparedness;
Autonomy through competitiveness;
Open to the world and autonomous;
An autonomous Union of values that leaves no one behind; and
A long-term budget for an autonomous Union…
Read more
The European Commission has published the Horizon Europe Work Programmes for 2026–2027, confirming EUR 14 billion in EU investment to support research and innovation across Europe over the next two years. In line with the EUDA mandate (1), we have reviewed the programmes and identified a set of upcoming Horizon Europe calls of relevance to drug-related research and innovation. These calls span multiple parts of the programme, including:
Cluster 1: Health — addressing prevention, mental health, non-communicable diseases and health systems.
Cluster 3: Civil Security for Society — including…
Read more
